Inpatient Hyperglycemia Management and COVID-19
- PDF / 354,957 Bytes
- 12 Pages / 595.276 x 790.866 pts Page_size
- 74 Downloads / 167 Views
REVIEW
Inpatient Hyperglycemia Management and COVID-19 Virginia Bellido
. Antonio Pe´rez
Received: September 10, 2020 / Accepted: November 3, 2020 Ó The Author(s) 2020
ABSTRACT Diabetes is one of the most common comorbidities in hospitalized patients with coronavirus disease 2019 (COVID-19). Inpatient hyperglycemia during this pandemic has been associated with worse outcomes, so it is mandatory to implement effective glycemic control treatment approaches for inpatients
V. Bellido Department of Endocrinology and Nutrition, Cruces University Hospital, Vizcaya, Spain V. Bellido Biocruces Bizkaia Health Research Institute, Vizcaya, Spain V. Bellido University of the Basque Country (UPV/EHU), Vizcaya, Spain A. Pe´rez (&) Department of Endocrinology and Nutrition, Santa Creu I Sant Pau Hospital, Barcelona, Spain e-mail: [email protected] A. Pe´rez Sant Pau Institute of Biomedical Research, Barcelona, Spain A. Pe´rez Autonomous University of Barcelona, Barcelona, Spain A. Pe´rez CIBER de Diabetes Y Enfermedades Metabo´licas Asociadas (CIBERDEM), Barcelona, Spain
with COVID-19. The shortage of personal protective equipment, the need to prevent staff exposure, or the fact that many of the healthcare professionals might be relatively unfamiliar with the management of hyperglycemia may lead to worse glycemic control and, consequently, a worse prognosis. In order to reduce these barriers, we intend to adapt established recommendations to manage hyperglycemia during this pandemic in critical and noncritical care settings.
Keywords: COVID-19; Diabetes; Hospitalized; Hyperglycemia; Inpatient; Insulin therapy; SARS-CoV-2
Diabetes Ther
Key Summary Points Diabetes is one of the most common comorbidities in hospitalized patients with coronavirus disease 2019 (COVID19). Inpatient hyperglycemia during the COVID-19 pandemic has been associated with worse outcomes, but improvement of glycemic control can reduce complications associated with hyperglycemia. Effective glycemic control treatment approaches for inpatients with COVID-19 are needed while, at the same time, limiting the exposure of healthcare professionals. An individualized approach adapting the established recommendations for the management of hyperglycemia in hospitalized patients may reduce the barriers during COVID-19 pandemic.
DIGITAL FEATURES This article is published with digital features, including a summary slide, to facilitate understanding of the article. To view digital features for this article go to https://doi.org/10.6084/ m9.figshare.13182836.
INTRODUCTION Diabetes is one of the most common comorbidities of coronavirus disease 2019 (COVID19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. The prevalence of diabetes among people affected by COVID-19 is not higher than that observed in the general population, suggesting that diabetes does not increase the risk of SARSCoV-2 infection, but can worsen the outcome of the disease [1, 2]. In fact, clinical studies have
found diabetes to be a major risk factor for disease
Data Loading...
